These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 32033144)

  • 1.
    Macalino SJY; Billones JB; Organo VG; Carrillo MCO
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32033144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications of Molecular Simulation in the Discovery of Antituberculosis Drugs: A Review.
    Hu JP; Wu ZX; Xie T; Liu XY; Yan X; Sun X; Liu W; Liang L; He G; Gan Y; Gou XJ; Shi Z; Zou Q; Wan H; Shi HB; Chang S
    Protein Pept Lett; 2019; 26(9):648-663. PubMed ID: 31218945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DFT based QSAR/QSPR models in the development of novel anti-tuberculosis drugs targeting Mycobacterium tuberculosis.
    Rajkhowa S; Deka RC
    Curr Pharm Des; 2014; 20(27):4455-73. PubMed ID: 24245759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Jagadeb M; Rath SN; Sonawane A
    J Biomol Struct Dyn; 2019 Aug; 37(13):3388-3398. PubMed ID: 30132739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extensively drug-resistant (XDR) tuberculosis: an old and new threat.
    Fattorini L; Migliori GB; Cassone A
    Ann Ist Super Sanita; 2007; 43(4):317-9. PubMed ID: 18209265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of DprE1 inhibitors for tuberculosis through integrated in-silico approaches.
    Dash S; Rathi E; Kumar A; Chawla K; Kini SG
    Sci Rep; 2024 May; 14(1):11315. PubMed ID: 38760437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New tuberculostatic agents targeting nucleic acid biosynthesis: drug design using QSAR approaches.
    Bueno RV; Braga RC; Segretti ND; Ferreira EI; Trossini GH; Andrade CH
    Curr Pharm Des; 2014; 20(27):4474-85. PubMed ID: 24245758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extensively drug-resistant tuberculosis: new strains, new challenges.
    Banerjee R; Schecter GF; Flood J; Porco TC
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):713-24. PubMed ID: 18847407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
    Centers for Disease Control and Prevention (CDC)
    MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4H-1,3-Benzothiazin-4-one a Promising Class Against MDR/XDR-TB.
    de Souza MVN; Nogueira TCM
    Curr Top Med Chem; 2019; 19(8):567-578. PubMed ID: 30834835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An integrated computational approach of molecular dynamics simulations, receptor binding studies and pharmacophore mapping analysis in search of potent inhibitors against tuberculosis.
    Agarwal S; Verma E; Kumar V; Lall N; Sau S; Iyer AK; Kashaw SK
    J Mol Graph Model; 2018 Aug; 83():17-32. PubMed ID: 29753941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico designing of domain B selective gyrase inhibitors for effective treatment of resistant tuberculosis.
    Kashyap A; Singh PK; Silakari O
    Tuberculosis (Edinb); 2018 Sep; 112():83-88. PubMed ID: 30205973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of novel quinoline-aminopiperidine derivatives as
    Wang J; Zhao C; Tu J; Yang H; Zhang X; Lv W; Zhai H
    J Biomol Struct Dyn; 2019 Jul; 37(11):2913-2925. PubMed ID: 30044186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pattern of first- and second-line drug resistance among pulmonary tuberculosis retreatment cases in Pakistan.
    Javaid A; Hasan R; Zafar A; Chaudry MA; Qayyum S; Qadeer E; Shaheen Z; Agha N; Rizvi N; Afridi MZ; Chima MK; Khan AR; Ghafoor A; Khan S; Awan SR; Akhtar S; Choudry K; Iqbal ZH; Ansarie M; Ahmad N
    Int J Tuberc Lung Dis; 2017 Mar; 21(3):303-308. PubMed ID: 28225340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance.
    Lohrasbi V; Talebi M; Bialvaei AZ; Fattorini L; Drancourt M; Heidary M; Darban-Sarokhalil D
    Tuberculosis (Edinb); 2018 Mar; 109():17-27. PubMed ID: 29559117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis.
    Fofana MO; Shrestha S; Knight GM; Cohen T; White RG; Cobelens F; Dowdy DW
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. QSAR based design of new antitubercular compounds: improved isoniazid derivatives against multidrug-resistant TB.
    Martins F; Ventura C; Santos S; Viveiros M
    Curr Pharm Des; 2014; 20(27):4427-54. PubMed ID: 24245762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoteric advancement in TB drugs and an overview on the anti-tubercular role of peptides through computational approaches.
    Khusro A; Aarti C; Barbabosa-Pliego A; Salem AZM
    Microb Pathog; 2018 Jan; 114():80-89. PubMed ID: 29174699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.